Aadi Bioscience reports Q1 2023 FYARRO sales of $5.9M, net loss $15.2M; PRECISION 1 interim analysis expected end 2023

Whitehawk Therapeutics, Inc.

2023-Q1 EPS reported -$0.57 revenue$5,867,000

FYARRO net product sales $5.9M, up 12% QoQ from $5.2M in Q4 2022 and $2.3M in Q1 2022.
Net loss $15.2M vs $13.9M in Q1 2022; cash $151.2M expected to fund operations into 2025.
PRECISION 1 trial enrolling evenly in TSC1/2 arms; >15 tumor types; interim efficacy analysis on 40 patients expected by year-end 2023.
Appointed Dr. Mohammad Hirmand to board; Phase 1/2 KRAS G12C combo trial with adagrasib expected to start dosing in Q2 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Whitehawk Therapeutics, Inc. reported the quarter ended March 31, 2023 results: revenue $5.9 million, net income $15.2 million.

Period: the quarter ended March 31, 2023
Revenue: $5.9 million
Net income: $15.2 million
Result: reported results

Exact text from the filing

Announces Financial Results and Operational Update for the First Quarter 2023 and Provides Update on PRECISION 1 Tumor Agnostic Trial Total 1Q 2023 revenue on FYARRO® sales of $5.9 million PRECISION 1 tumor agnostic trial enrolling equally in TSC1 and TSC2 arms with more than 15 discreet tumor types represented Interim analysis on 40 patients with appropriate

View on SEC.gov

23 earnings releases filed in the last 30 days. Browse all earnings releases →

Whitehawk Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-017031

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.